Crave Control supports the synthesis of the brain reward neurotransmitters (like serotonin and catecholamines) and through its effect on the natural opioids will, by virtue of inhibiting GABA, cause a significant release of dopamine at the nucleus accumbens. This constant release of possibly therapeutic amounts of dopamine, leads to proliferation of D2 receptors, thereby promoting appetite suppression and reducing overall craving in general. FUNCTIONSEarly biochemical textbooks reference certaincarboxypeptidase inhibitors, of which one of the mostpotent amino acids included was D-Phenylalanine. Yearslater, studies of D-Phenylalanine demonstrated threeimportant roles for the amino acid; analgesic, anti-inflammatory and anti-craving. Further studies revealedthat certain enzymes were responsible for the breakdownof brain opioid peptides. Brain studies indicated that DPhenylalanine inhibited the enzyme,enkephalinase. Injections of D-Phenylalanine resulted ininhibition of enkephalinase and higher levels of the brainopioid enkephalin. While D-Phenylalanine alone isconsidered a drug, DL-Phenylalanine, which is in CraveControl, is considered a neutraceutical, and is as effectiveas D-Phenylalanine, only at a slightly higher dose.Further studies have demonstrated that low dopamine D2receptors and/or low amounts of dopamine released at thesynapse in the brain, will lead to craving behavior. It isfurther understood that if D2 receptors are continuallystimulated, a positive feedback will induce thedevelopment of additional D2 receptors. Therefore, if D2receptors are compromised in the human, then stimulatingD2 receptors with dopamine will reduce craving behavior.Anti-craving behavior can be induced if there is a meansof continually releasing dopamine at the reward site of thebrain in the mesolimbic system, and even in a geneticallycompromised individual, existing craving behavior can beimproved.In addition to DL-Phenylalanine, Crave Control containsthe necessary ingredients to properly utilize DLPhenylalanine and increase dopamine production.Ingredients such as L-Tyrosine, L-Glutamine, 5-HTP,Rhodiola Rosea and P5P help to ensure that healthy levelsof dopamine are encouraged to address “RewardDeficiency Syndrome” which features multipleexpressions including overeating and carbohydratebinging. In conclusion, Crave Control causes the synthesisof the brain reward neurotransmitters such as serotoninand catecholamines. And through its effect on naturalopioids, will by inhibiting GABA, cause a significantrelease of dopamine at the nucleus accumbens. Thisrelease of increased amounts of dopamine creates aproliferation of D2 receptors, thereby reducing cravingsfor carbohydrates. This same improvement in the cravingprocess can also be approached in other behaviors wherecraving is a major concern.INDICATIONSCrave Control may be a useful dietary supplement inindividuals who exhibit dopamine deficient cravings orwho are attempting to increase their D2 receptors anddopamine levels in the brain.
Related
Related
Related
Related